Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Ibrutinib has demonstrated high response rates in B-cell lymphomas but a lot of ibrutinib-treated patients relapse with resistance. This study unified TME-mediatedde novoand acquired drug resistance through B-cell receptor signalling and PI3K-AKT-mTOR axis and provides a combination therapeutic stra...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/87b74c23a81c4b28a5b297ad5bef630b |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|